Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma

NCT06553040 is registered in ClinicalTrials.gov with Ege University as lead sponsor.

NCT NCT06553040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06553040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma
Lead sponsor
Ege University
Phase
Observational
Overall status
Completed
Start date
January 1, 2017
Completion date
January 1, 2023
Enrollment
87 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer, pancreatic neoplasms